About Us

We are committed to your mission of optimizing patient access with evidence of value, effectiveness, and safety.

Who We Are

Evidera is the peri- and post-approval business unit within Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO), and is the preeminent provider of evidence-based solutions to demonstrate the real-world effectiveness, safety, and value of biopharmaceutical and biotechnology products from early development through loss of exclusivity. We provide integrated scientific expertise and global operational capabilities to help you generate the evidence needed to optimize the market access and commercial potential of your products.

Evidera was acquired by PPD in 2016 and originally created in 2013 as an independent company under the ownership of Symphony Technology Group following the acquisition of long-standing health economics, outcomes research, market access, epidemiology, and data analytics practices from United BioSource Corporation (UBC). Evidera has over 30 years of leadership and experience and its legacy brands include MEDTAP, Caro Research, Abt Bio-Pharmaceutical Solutions, MetaWorks, Total Healthcare Group, and Archimedes.

Our Offerings

  • Interventional studies
  • Real-world evidence
  • Patient-centered research
  • Pragmatic/adaptive studies
  • Modeling and meta research
  • Market access
  • Medical writing
  • Evalytica

Our Expertise and Global Reach

  • 500+ staff representing over 35 nationalities around the world
  • 2,200+ peer reviewed publications, averaging 150+ per year
  • 8 primary offices across North America and Europe
  • 15 average years of experience for scientific and consulting staff
  • 75% of researchers have advanced degrees across a range of disciplines
  • 1,100+ studies in progress across all major therapeutic areas
  • 150+ drugs/therapies supported in the past year, including 9 of the top 10 selling drugs (projected through 2022) in the past 5 years
  • Supported reversal of multiple NICE decisions and hundreds of successful HTA and regulatory filings
Back to Top